Unknown

Dataset Information

0

Captopril alleviates lung inflammation in SARS-CoV-2-infected hypertensive mice.


ABSTRACT: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic agent responsible for the global coronavirus disease 2019 (COVID-19) pandemic. Numerous studies have demonstrated that cardiovascular disease may affect COVID-19 progression. In the present study, we investigated the effect of hypertension on viral replication and COVID-19 progression using a hypertensive mouse model infected with SARS-CoV-2. Results revealed that SARS-CoV-2 replication was delayed in hypertensive mouse lungs. In contrast, SARS-CoV-2 replication in hypertensive mice treated with the antihypertensive drug captopril demonstrated similar virus replication as SARS-CoV-2-infected normotensive mice. Furthermore, antihypertensive treatment alleviated lung inflammation induced by SARS-CoV-2 replication (interleukin (IL)-1β up-regulation and increased immune cell infiltration). No differences in lung inflammation were observed between the SARS-CoV-2-infected normotensive mice and hypertensive mice. Our findings suggest that captopril treatment may alleviate COVID-19 progression but not affect viral replication.

SUBMITTER: Gao WC 

PROVIDER: S-EPMC8455464 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-SCDT-10_15252-EMMM_202317580 | biostudies-other
| PRJEB53059 | ENA
| S-SCDT-EMBOJ-2020-106267 | biostudies-other
| S-EPMC9264370 | biostudies-literature
| S-EPMC10421285 | biostudies-literature
2023-06-05 | GSE223056 | GEO
| EMPIAR-10753 | biostudies-other
2022-05-30 | GSE205014 | GEO
| S-EPMC7578095 | biostudies-literature
| S-EPMC2762542 | biostudies-other